Synthetic Biologics, Inc. (NYSEAMERICAN:SYN) has been given a consensus rating of “Hold” by the six research firms that are currently covering the company, Marketbeat reports. Two research analysts have rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating on the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $2.63.
Several research firms recently weighed in on SYN. HC Wainwright reaffirmed a “buy” rating on shares of Synthetic Biologics in a report on Friday. Zacks Investment Research raised shares of Synthetic Biologics from a “sell” rating to a “buy” rating and set a $0.25 price objective for the company in a report on Saturday, May 12th. Finally, Griffin Securities downgraded shares of Synthetic Biologics from a “buy” rating to a “hold” rating in a report on Wednesday, May 9th.
Hedge funds have recently bought and sold shares of the stock. Citadel Advisors LLC raised its position in Synthetic Biologics by 312.1% in the fourth quarter. Citadel Advisors LLC now owns 241,797 shares of the company’s stock worth $122,000 after acquiring an additional 183,120 shares in the last quarter. Virtu Financial LLC raised its position in Synthetic Biologics by 256.1% in the fourth quarter. Virtu Financial LLC now owns 299,577 shares of the company’s stock worth $152,000 after acquiring an additional 215,440 shares in the last quarter. Blair William & Co. IL raised its position in Synthetic Biologics by 14.8% in the first quarter. Blair William & Co. IL now owns 1,980,857 shares of the company’s stock worth $631,000 after acquiring an additional 255,096 shares in the last quarter. Finally, 683 Capital Management LLC bought a new stake in Synthetic Biologics in the fourth quarter worth about $762,000.
Synthetic Biologics (NYSEAMERICAN:SYN) last announced its quarterly earnings results on Tuesday, May 8th. The company reported ($0.02) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.05) by $0.03.
About Synthetic Biologics
Synthetic Biologics, Inc, a late-stage clinical company, develops therapeutics designed to preserve the microbiome to protect and restore the health of patients. Its lead product candidates are in Phase III development, such as SYN-004 that is designed to protect the gut microbiome from the effects of commonly used intravenous (IV) beta-lactam antibiotics for the prevention of C.
Receive News & Ratings for Synthetic Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synthetic Biologics and related companies with MarketBeat.com's FREE daily email newsletter.